COVID-19 Quick Takes: Moderna won’t challenge vaccine IP, wins contract for mobile GMP manufacturing

Moderna won’t enforce COVID-19 IP during pandemic
Moderna Inc. (NASDAQ:MRNA) said on Thursday it will not enforce its COVID-19 related patents against vaccine developers addressing SARS-CoV2 while the pandemic continues. It added that it is willing to out-license its IP for COVID-19 vaccines after the pandemic ends.

DARPA to fund Moderna mobile manufacturing prototype
Moderna also announced that the U.S. Defense Advanced Research Projects Agency has committed to provide up to $56 million for the biotech to develop a mobile manufacturing prototype for rapid GMP production of vaccines and therapeutics. The agreement builds on a 2013 grant...